Fennec Pharmaceuticals Inc.
NASDAQ•FENC
CEO: Mr. Rostislav Raykov
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-09-15
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Contact Information
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709, United States
919-636-4530
Market Cap
$211.03M
P/E (TTM)
-30.8
37
Dividend Yield
--
52W High
$9.92
52W Low
$4.68
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$12.46M+78.69%
4-Quarter Trend
EPS
-$0.02-90.48%
4-Quarter Trend
FCF
$1.49M-167.68%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
PEDMARK Sales Growth Strong PEDMARK net product sales reached $30.9M for nine months, up $9.2M from $21.7M in prior year period.
Q3 Net Loss Significantly Narrows Third quarter net loss reduced to $(638K) USD, a substantial improvement from $(5.7M) USD loss reported in Q3 2024.
Norgine Royalty Revenue Stream Recognized $390K USD in Norgine royalties within product sales for the nine months ended September 30, 2025.
Ending Cash Position Secure Cash and equivalents totaled $21.9M USD as of September 30, 2025, supporting near-term operations.
Risk Factors
Operating Cash Flow Negative Nine months ended September 30, 2025 showed net cash used in operating activities of $(6.5M) USD compared to inflow.
Ongoing Patent Litigation Risk Active patent infringement suit against CIPLA entities continues, posing potential legal and financial uncertainty.
Accumulated Deficit Large Accumulated deficit reached $(224.6M) USD as of September 30, 2025, impacting overall equity position.
Reliance on Single Product Business heavily relies on PEDMARK commercialization success; future growth tied to market penetration efforts.
Outlook
Norgine European Expansion Norgine announced launch of PEDMARQSI in Germany and U.K. early 2025, expanding market reach.
Strategic Alternatives Pursued Company continues pursuing strategic alternatives, including collaborations, to fund future capital requirements and R&D efforts.
Term Loan Maturity Approaching Remaining Second Closing Notes principal balance of approximately $19.5M USD (inclusive of PIK) matures in August 2027.
Patent Defense Efforts Continue Actively defending key PEDMARK patents against generic challenges, including recent filing of suit against CIPLA.
Peer Comparison
Revenue (TTM)
ENTA$65.32M
TRDA$61.52M
$38.79M
Gross Margin (Latest Quarter)
ENTA100.0%
ASMB100.0%
94.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SLS | $449.02M | -17.8 | -95.2% | 1.2% |
| TRDA | $436.85M | -4.6 | -26.4% | 12.7% |
| EPRX | $301.32M | -11.8 | -62.6% | 0.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
16.3%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 9, 2026
EPS:$0.01
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 13, 2025|Revenue: $12.46M+78.7%|EPS: $-0.02-90.5%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 14, 2025|Revenue: $9.65M+32.9%|EPS: $-0.12-40.0%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 14, 2025|Revenue: $8.75M-65.5%|EPS: $-0.04-109.0%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 26, 2025|Revenue: $47.54M+123.7%|EPS: $-0.02+97.3%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 8, 2024|Revenue: $6.97M+7.0%|EPS: $-0.21+200.0%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 13, 2024|Revenue: $7.26M+118.4%|EPS: $-0.20-4.8%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 14, 2024|Revenue: $25.38M+1413.2%|EPS: $0.47-262.1%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 29, 2024|Revenue: $21.25M+1284.5%|EPS: $-0.60+36.8%Miss